CureVac
German bio-pharmaceutical company
Follow CureVac on Notably News to receive short updates to your email — rarely!
| 2023 | CureVac adjusted its goal for obtaining official approval for the marketability of an improved Covid-19 vaccine, now projected for 2023 at the earliest. |
| 2022 | CureVac determined that an approval-relevant study for the new vaccine could only be carried out in the fourth quarter of 2022. |
| January 2022 | The start of the phase 1 study with the product candidate CV2CoV was postponed from the fourth quarter of 2021 to the first quarter of 2022. |
| 2021 | CureVac partnered with GlaxoSmithKline (GSK) to develop a new generation of mRNA-based COVID-19 vaccines, with human testing planned for late 2021. |
| October 2021 | The company decided to abandon further research and development of CVnCoV and announced a collaboration with GSK to develop improved mRNA vaccine technology. |
| June 16 2021 | CureVac announced results of Phase III trials showing its mRNA vaccine had an efficacy of 47%, which fell short of the European Medicines Agency's target of at least 50%. |
| February 12 2021 | CureVac initiated a rolling submission with the European Medicines Agency (EMA) for their vaccine candidate, starting a time-optimized review process for potential market authorization. |
| January 2021 | CureVac announced a clinical development collaboration with Bayer for its COVID-19 vaccine CVnCoV (active ingredient zorecimeran). |
| December 2020 | CureVac began a Phase III clinical trial of CVnCoV COVID-19 vaccine with 36,500 participants, with Bayer providing clinical trial support and international logistics. |
| August 2020 | Elon Musk reviewed the Tesla-CureVac project while in Germany, and the companies filed a joint patent on the RNA microfactory technology. |
| August 14 2020 | CureVac began public trading on the NASDAQ exchange under the ticker symbol CVAC, raising an unspecified amount in its initial public offering (IPO). |
| July 2020 | Elon Musk announced an agreement between Tesla and CureVac to produce portable 'RNA microfactories' for manufacturing CureVac's COVID-19 vaccine candidate, with the ability to produce over 100,000 doses in approximately two weeks. |
| June 2020 | Clinical trials for the CureVac COVID-19 Vaccine (CVnCoV) began. The German Federal Government invested €300 million in CureVac, with KfW acquiring a stake of approximately 23% in the company. |
| March 16 2020 | CureVac issues a public statement on Twitter denying receiving any offer from the U.S. government to relocate, rejecting press allegations about potential negotiations. |
| March 11 2020 | Daniel Menichella is replaced as CEO of CureVac by the company's founder Ingmar Hoerr. |
| March 2 2020 | CureVac CEO Daniel Menichella meets with U.S. President Donald Trump at the White House, amid reports of potential U.S. government attempts to persuade the company to relocate. |
| February 2019 | The Coalition for Epidemic Preparedness Innovations (CEPI) awarded CureVac a $34 million grant to develop a proprietary 'RNA printer' prototype for rapid vaccine production. |
| May 2018 | CureVac reached approximately 375 employees by this time. |
| 2017 | CureVac received investments of approximately an unspecified amount in the form of equity and was valued at an unspecified amount. |
| 2016 | CureVac began construction on a production facility in accordance with its deal with Eli Lilly and Company. |
| September 2015 | CureVac entered into a collaboration with the International AIDS Vaccine Initiative (IAVI) to accelerate AIDS vaccine development and opened a United States hub in Boston, Massachusetts. |
| March 2015 | The Bill & Melinda Gates Foundation agreed to provide separate funding for several prophylactic vaccine projects using CureVac's mRNA platform. |
| September 2014 | CureVac licensed global rights for its Phase I candidate CV9202 to Boehringer Ingelheim for trials in non-small cell lung cancer treatments. |
| July 2014 | CureVac signed an exclusive license agreement with Sanofi Pasteur to develop and commercialize an mRNA-based prophylactic vaccine. |
| March 2014 | CureVac won a prize awarded by the European Commission to stimulate new vaccine technologies. |
| 2013 | CureVac announced a partnership with the Cancer Research Institute and Ludwig Cancer Research to enable clinical testing of novel cancer immunotherapy treatment options. |
| October 2013 | CureVac launched a collaboration with Janssen Pharmaceuticals Inc. (Johnson & Johnson) for developing novel flu vaccines. |
This contents of the box above is based on material from the Wikipedia article CureVac, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.